Top Markets
#1 Black Phoenix Black Phoenix +826.64%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.17%
#3 Beam Beam +24.88%
#4 Bless Bless +21.52%
#5 Tutorial Tutorial +21.07%
#6 SAFEcoin SAFEcoin +20.45%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +19.37%
#8 Magma Finance Magma Finance +17.16%
#9 THORChain THORChain +17.07%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +15.57%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
China Resources Double-Crane Pharmaceutical Co.,Ltd. China Resources Double-Crane Pharmaceutical Co.,Ltd.

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062
Rangering i aksjer #5807
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its... China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its affiliated companies, operates as a prominent pharmaceutical enterprise within the People's Republic of China. The company's diverse product range includes various types of infusion solutions, available in soft bags, plastic and glass bottles, as well as inner-sealed and blend polypropylene bags. Its manufacturing capabilities extend to numerous injectable products, such as levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, and sodium chloride injections, among others. Additionally, it supplies vital dialysate solutions for both peritoneal and hemodialysis. A substantial part of its portfolio is dedicated to addressing cardiovascular and cerebrovascular diseases, featuring medications like compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, and edaravone. Furthermore, China Resources Double-Crane offers treatments for endocrinological conditions and a selection of pediatric drugs, notably including pediatric compound amino acid injections. The company's offerings also encompass nutritional supplements, such as vitamins E and C, and a variety of anti-infective pharmaceuticals. Headquartered in Beijing, the People's Republic of China, China Resources Double-Crane Pharmaceutical Co.,Ltd. is an affiliate of Beijing Pharmaceutical Group Co., Ltd.
Aksjekurs
$2.34
Markedsverdi
$2.43B
Endring (1 dag)
-0.37%
Endring (1 år)
-14.62%
Land
CN
Handel China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062)

Kategori

Healthcare
Driftsmargin for China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062)
Driftsmargin per 2026 TTM: 0.00%
Ifølge China Resources Double-Crane Pharmaceutical Co.,Ltd. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 0.00%. Ved slutten av 2026 hadde selskapet en driftsmargin på 0.00%.
Historikk for driftsmargin for China Resources Double-Crane Pharmaceutical Co.,Ltd. fra 2026 til 2026
Driftsmargin ved slutten av hvert år
År Driftsmargin Endre
Ikke nok data for de angitte datoene.
Driftsmargin for lignende selskaper eller konkurrenter
Selskap Driftsmargin Forskjell i driftsmargin Land
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
0.00% -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
0.00% -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
0.00% -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
0.00% -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
22.93% -
IN
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.